- Home
- FOF vs INBX Comparison
FOF vs INBX Comparison
Compare FOF & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- INBX
- Stock Information
- Founded
- FOF 2006
- INBX 2010
- Country
- FOF United States
- INBX United States
- Employees
- FOF N/A
- INBX N/A
- Industry
- FOF Investment Managers
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- FOF Finance
- INBX Health Care
- Exchange
- FOF Nasdaq
- INBX Nasdaq
- Market Cap
- FOF 354.8M
- INBX 345.8M
- IPO Year
- FOF N/A
- INBX 2020
- Fundamental
- Price
- FOF $13.04
- INBX $27.52
- Analyst Decision
- FOF
- INBX Hold
- Analyst Count
- FOF 0
- INBX 2
- Target Price
- FOF N/A
- INBX N/A
- AVG Volume (30 Days)
- FOF 58.7K
- INBX 113.1K
- Earning Date
- FOF 01-01-0001
- INBX 11-13-2025
- Dividend Yield
- FOF 9.07%
- INBX N/A
- EPS Growth
- FOF N/A
- INBX N/A
- EPS
- FOF N/A
- INBX N/A
- Revenue
- FOF N/A
- INBX $1,400,000.00
- Revenue This Year
- FOF N/A
- INBX N/A
- Revenue Next Year
- FOF N/A
- INBX N/A
- P/E Ratio
- FOF N/A
- INBX N/A
- Revenue Growth
- FOF N/A
- INBX N/A
- 52 Week Low
- FOF $9.59
- INBX $10.81
- 52 Week High
- FOF $11.75
- INBX $30.23
- Technical
- Relative Strength Index (RSI)
- FOF 52.53
- INBX 58.56
- Support Level
- FOF $13.00
- INBX $27.51
- Resistance Level
- FOF $13.13
- INBX $30.23
- Average True Range (ATR)
- FOF 0.09
- INBX 1.47
- MACD
- FOF -0.01
- INBX -0.09
- Stochastic Oscillator
- FOF 27.78
- INBX 54.53
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.